Structure of Futibatinib
CAS No.: 1448169-71-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
FGFR-IN-1 is a potent and highly selective FGFR inhibitor, used for antitumor treatment.
Synonyms: TAS-120
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1448169-71-8 |
Formula : | C22H22N6O3 |
M.W : | 418.45 |
SMILES Code : | C=CC(N1C[C@@H](N2N=C(C#CC3=CC(OC)=CC(OC)=C3)C4=C(N)N=CN=C42)CC1)=O |
Synonyms : |
TAS-120
|
MDL No. : | MFCD29037352 |
InChI Key : | KEIPNCCJPRMIAX-HNNXBMFYSA-N |
Pubchem ID : | 71621331 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
MCF10A cells | 0.2 µM | 3 hours 45 minutes | To assess the effect of Futibatinib on FGFR signaling pathways, results showed Futibatinib significantly inhibited phosphorylation of Akt and ERK1/2 | PMC10657448 |
ICC13-7 cells | 10 nM | 4 hours | Evaluate the signaling inhibition effect of Futibatinib on FGFR2-PHGDH fusion protein | PMC10767308 |
CCLP-1 cells | 50 nM | 4 hours | Evaluate the signaling inhibition effect of Futibatinib on FGFR2-PHGDH fusion protein | PMC10767308 |
H69-FGFR2-BICC1/BRAF V600E cells | 40 μM | 72 hours | To evaluate the impact of BRAF V600E mutation on Futibatinib sensitivity, results showed BRAF V600E mutation significantly reduced the inhibitory effect of Futibatinib. | PMC11900356 |
H69-FGFR2-BICC1/KRAS G12D cells | 40 μM | 72 hours | To evaluate the impact of KRAS G12D mutation on Futibatinib sensitivity, results showed KRAS G12D mutation significantly reduced the inhibitory effect of Futibatinib. | PMC11900356 |
H69 cells | 12.5 nM | 72 hours | To evaluate the sensitivity of Futibatinib in FGFR2-BICC1 fusion cells, results showed Futibatinib significantly inhibited the growth of fusion cells. | PMC11900356 |
SCMC | 11.7 µM | 72 hours | Evaluate the inhibitory effect of Futibatinib on SCMC cells, results show Futibatinib has weaker inhibitory effect on SCMC cells. | PMC10452847 |
RH4 | 6.64 µM | 72 hours | Evaluate the inhibitory effect of Futibatinib on RH4 cells, results show Futibatinib has weaker inhibitory effect on RH4 cells. | PMC10452847 |
RMS559 | 0.48 µM | 72 hours | Evaluate the inhibitory effect of Futibatinib on RMS559 cells, results show Futibatinib significantly inhibits cell growth. | PMC10452847 |
Ba/F3 TEL-FGFR4 | 1.33 nM | 72 hours | Evaluate the inhibitory effect of Futibatinib on Ba/F3 TEL-FGFR4 cells, results show Futibatinib selectively kills cells through FGFR4 inhibition. | PMC10452847 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Rat | Sprague-Dawley rats | Oral | 10 mg/kg | Single dose | For pharmacokinetic study, to determine the concentration of orelabrutinib in plasma | PMC9486086 |
Female athymic nude mice | Breast cancer PDX models | Oral | 15 mg/kg | Daily for 28 days or until tumor diameter reached 1.5 cm3 | To evaluate the antitumor activity of Futibatinib in FGFR-altered breast cancer PDX models, results showed significant tumor growth inhibition in FGFR2-amplified and FGFR2 Y375C mutant models | PMC10657448 |
Nude mice | FGFR2-BICC1 and FGFR2-BICC1/KRAS G12D xenograft models | Oral gavage | 5 mg/kg Futibatinib and 6 mg/kg Binimetinib | Once daily for 14 days | To evaluate the antitumor effect of Futibatinib alone or in combination with Binimetinib in FGFR2-BICC1 and FGFR2-BICC1/KRAS G12D xenograft models, results showed combination therapy significantly inhibited tumor growth in FGFR2-BICC1 model but had limited effect in FGFR2-BICC1/KRAS G12D model. | PMC11900356 |
NOD SCID Gamma (NSG) mice | RMS559, RH4, and SCMC xenograft models | Oral gavage | 5-25 mg/kg | Once daily for three weeks | Evaluate the efficacy of Futibatinib monotherapy in RMS xenograft models, results show Futibatinib monotherapy had no significant effect on tumor growth or survival. | PMC10452847 |
NOD/SCID gamma mice | Patient-derived xenograft (PDX) model | Not used | 6 mg/kg | Once daily for up to 50 days | Evaluate the antitumor activity of Futibatinib against FGFR2 kinase domain mutations in PDX models | PMC7616615 |
NSG mice | CCLP-1 xenograft model | Oral gavage | 6 mg/kg | Once daily for 10 days | Evaluate the in vivo efficacy of Futibatinib on FGFR2-PHGDH-N550K mutant tumors | PMC10767308 |
NSG mice | CCLP-1 xenograft model | Oral gavage | 6 mg/kg | Once daily for 10 days | Evaluate the in vivo efficacy of futibatinib against FGFR2-N550K mutation | PMC10767308 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT05727176 | Advanced Cholangiocarcinoma|FG... More >>FR2 Fusions|Gene Rearrangement Less << | PHASE2 | RECRUITING | 2025-12-26 | University of California San D... More >>iego UCSD - Moores Cancer Center, La Jolla, California, 92093, United States|Tampa General Hospital Cancer Institute, Tampa, Florida, 33606, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|Texas Oncology, Abilene, Texas, 79606-5208, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, 75203, United States|Texas Onc Methodist (Charlton), Dallas, Texas, 75237, United States|Center for Oncology and Blood Disorders, Houston, Texas, 77030, United States|CEMIC, Caba, 1431, Argentina|Hospital Britanico, Ciudad Autonoma de Buenos Aires, AEB1280, Argentina|Sanatorio de la Mujer, Rosario, S2013, Argentina|St Vincent's Hospital Sydney - The Kinghorn Cancer Centre, Sydney, New South Wales, 2010, Australia|Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center, Melbourne, Victoria, 3004, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, 6008, Australia|Instituto do Cancer do Estado de Sao Paulo, Cerqueira César, 01246-000, Brazil|IOP - Instituto de Oncologia do Parana, Curitiba, 80530-010, Brazil|Hospital Erasto Gaertner, Curitiba, 81520-060, Brazil|Hospital de Base de Sao Jose do Rio Preto, S?o José Do Rio Preto, 15090-000, Brazil|Fundacao Antonio Prudente - A.C.Camargo Cancer Center, S?o Paulo, 01508-010, Brazil|Guangdong Provincial People's Hospitall, Guangzhou, Guangdong, 510080, China|Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China|Jilin Cancer Hospital, Changchun, Jilin, 130028, China|Shandong University - Shandong Cancer Hospital, Jinan, Shandong, 250117, China|West China Hospital- Sichuan University, Chengdu, Sichuan, 610041, China|Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, 310016, China|Shanghai Gobroad Cancer Hospital China Pharmaceutical University, Shanghai, 200123, China|Tongji University Shanghai East Hospital, Shanghai, China|The University of Hong Kong, Hong Kong Island, 999077, Hong Kong|The Chinese University of Hong Kong Prince of Wales Hospital, New Territories, 999077, Hong Kong|Policlinico S. Orsola-Malpighi, Bologna, 40138, Italy|IRCCS Humanitas Research Hospital, Rozzano, 20089, Italy|AOUI Verona - Ospedale Borgo Roma, Verona, 37134, Italy|Tohoku University Hospital, Sendai, Miyagi, 980-8574, Japan|National Cancer Center Hospital East, Kashiwa-Shi, 277-0882, Japan|Nagasaki University Hospital, Nagasaki-shi, 852-8501, Japan|Nagoya University Hospital, Nagoya-shi, 466-8560, Japan|Osaka Metropolitan University Hospital, Osaka-Fu, 558-8585, Japan|Inje University Haeundae Paik Hospital, Busan, 48108, Korea, Republic of|Dong-A University Hospital, Busan, 49201, Korea, Republic of|Kyungpook National University Hospital, Daegu, 41944, Korea, Republic of|Gyeongsang National University Hospital, Jinju, 52727, Korea, Republic of|CHA Bundang Medical Center, Seongnam, 13532, Korea, Republic of|Yonsei University Health System - Severance Hospital, Seoul, 03722, Korea, Republic of|The Catholic University of Korea, St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Szpital Wojewdzki w Koszalinie im. Mikoaja Kopernika, Koszalin, 75-581, Poland|Centrum Onkologii Ziemi Lubelskiej im. w. Jana z Dukli, Lublin, 20-0920, Poland|Europejskie Centrum Zdrowia Otwock Sp. Z.o.o., Otwock, 05-400, Poland|Centrum Onkologii-Instytut im. Marii Sk?odowskiej - Curie, Warszawa, 02-034, Poland|Funda??o Champalimaud, Lisboa, 1400-038, Portugal|Centro Hospitalar Lisboa Norte CHLN EPE - Hospital de Santa Maria, Lisbon, 1649-035, Portugal|Hospital Vall d'Hebron, Barcelona, 08035, Spain|Institut Català d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals, Barcelona, 08908, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Clinica Universidad de Navarra, Medical Oncology Service (Mariano Ponz Sarvise), Madrid, 28027, Spain|Hospital Universitario Fundación Jimenez Díaz, Madrid, 28040, Spain|Hospital Universitario 12 de octubre, Madrid, 28043, Spain|Clinica Universidad de Navarra, Pamplona, 31008, Spain Less << |
NCT04507503 | Advanced Cholangiocarcinoma | APPROVED_FOR_MARKETING | - | Banner MD Anderson, Gilbert, A... More >>rizona, 85234, United States|University of California, San Francisco (UCSF), San Francisco, California, 94143, United States|UCLA Division of Hematology-Oncology, Santa Monica, California, 90404, United States|Mount Sinai Center of Florida, Miami Beach, Florida, 33140, United States|Advent Health Orlando, Orlando, Florida, 32804, United States|University of Chicago, Chicago, Illinois, 60637, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Kansas Cancer Center, Lee's Summit, Missouri, 64064, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|MD Anderson, Houston, Texas, 77030, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Aurora Cancer care, Grafton, Wisconsin, 53024, United States Less << | |
NCT02052778 | Cholangiocarcinoma|Urothelial ... More >>Cancer|Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors|Primary CNS Tumors|Breast Cancer|Gastric Cancer Less << | PHASE1|PHASE2 | COMPLETED | 2021-05-29 | Banner MD Anderson Cancer Cent... More >>er, Gilbert, Arizona, 85234, United States|Mayo Clinic (AZ), Scottsdale, Arizona, 85259, United States|The University of Arizona Cancer Center - North Campus, Tucson, Arizona, 85719, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|UCSF Helen Diller Family Comprehensive Cancer Center. Mission Bay, San Francisco, California, 94158, United States|Cancer Treatment Centers of America, Newnan, Georgia, 30265, United States|Cancer Treatment Centers of America Zion, IL, Zion, Illinois, 60099, United States|The University of Kansas Cancer Center, Fairway, Kansas, 66205, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institution, Boston, Massachusetts, 02215, United States|Wayne State Universtity (Karmanos Cancer Institute), Detroit, Michigan, 48201, United States|Mayo Clinic (MN), Rochester, Minnesota, 55905, United States|New Mexico Cancer Care Alliancer, Albuquerque, New Mexico, 87106, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Sidney Kimmel Cancer Center at Jefferson, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Greenville Health System ITOR,Clinical Research Unit, Greenville, South Carolina, 29605, United States|Spartanburg Medical Center, Spartanburg, South Carolina, 29303, United States|Mary Crowley Cancer Research - Medical City, Dallas, Texas, 75230, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, 84112, United States|University of Virginia Cancer Center, Charlottesville, Virginia, 22903, United States|Virginia Mason Cancer Center, Seattle, Washington, 98101, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, 53792, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Royal Melbourne Hospital, Melbourne, Australia|Sunnybrook Research Institue, Toronto, M4N3M5, Canada|Centre Léon Bérard Bat, Lyon, Cedex, 69373, France|Institut Bergonie, Bordeaux, 33076, France|Hospices Civils de Lyon, Bron, 69677, France|Pitié-Salpêtrière Hospital, Paris, 75013, France|Rennes, Centre Eugène Marquis, Rennes cedex, 35042, France|Institute Goustave-Roussy-DITEP, Villejuif, 94805, France|University Hospital Essen, West German Cancer Center, Department of Medical Oncology, Essen, 45147, Germany|The Chinese University of Hong Kong, Sha Tin, Hong Kong|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, 20133, Italy|UOC Oncologia Medica 1 I"V - Istituto Oncologico Veneto - IRCCS, Padova, 35128, Italy|Hokkaido University Hospital, Hokkaido, 060-8648, Japan|Kyoto University Hospital, Department of Clinical Pharmacology and Therapeutics, Kyoto, 606-8507, Japan|Tohoku University Hospital, Miyagi, 980-8574, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|Yonsei University, Severance Hospital (Seoul), Seoul, 03722, Korea, Republic of|ASAN Medical Center (Seoul), Seoul, 05505, Korea, Republic of|Samsung Medical Center (Seoul), Seoul, 06351, Korea, Republic of|Seoul National University Hospital, Seoul, 110-744, Korea, Republic of|University Hospital Jenna, Jenna, 07740, Netherlands|Val D'Hebron University Hospital, Barcelona, 08035, Spain|Hospital Clinic i Provincial de Barcelona,, Barcelona, 08036, Spain|University Hospital Ramón y Cajal, Madrid, 28034, Spain|Centro Integral Oncológico Clara Campal - Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10048, Taiwan|Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|Sarah Cannon Research Institute, London, W1G 6AD, United Kingdom|University College London Hospital, London, W1T 7HA, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom Less << |
NCT04189445 | Advanced or Metastatic Solid T... More >>umor|Advanced or Metastatic Gastric or Gastroesophageal Cancer|Myeloid or Lymphoid Neoplasms (MLN) Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-03-31 | Banner MD Anderson Cancer Cent... More >>er, Gilbert, Arizona, 85234-2165, United States|UCLA Medical Center, Los Angeles, California, 90404, United States|Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215-5400, United States|Henry Ford Hospital, Woodhaven, Michigan, 48183, United States|Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City, Oklahoma, 73120, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 53705, United States|Houston Methodist Cancer Center, Houston, Texas, 77030, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, United States|Institut Jules Bordet, Bruxelles, 1000, Belgium|Centre Antoine Lacassagne, Nice, Alpes Maritimes, 06200, France|Centre Paul Strauss, Strasbourg, Bas Rhin, 67000, France|Centre Georges Fran?ois Leclerc, Dijon, C?te-d'Or, 21079, France|Institut Bergonié, Bordeaux, Gironde, 33076, France|H?pital Saint-Louis, Paris Cedex 10, Paris, 75475, France|Centre Léon Bérard, Lyon, Rhone, 69008, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, Rhone, 69495, France|Institut Gustave Roussy, Villejuif, Val De Marne, 94805, France|Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg, 79106, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Baden Wuerttemberg, 69120, Germany|Universitaetsklinikum Koeln, Koeln, Nordrhein Westfalen, 50924, Germany|The University of Hong Kong, Hong Kong, Hong Kong|Hong Kong United Oncology Centre, Jordon, 0000, Hong Kong|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Forli - Cesena, 47014, Italy|Ospedale Sacro Cuore Don Calabria, Negrar, Verona, 37024, Italy|Azienda Ospedaliera Universitaria Careggi, Florence, 50134, Italy|IEO Istituto Europeo di Oncologia, Milano, 20141, Italy|Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Trento), Verona, 37124, Italy|Aichi Cancer Center Hospital, Nagoya-shi, Aichi-Ken, 464-8681, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba-Ken, 277-8577, Japan|NHO Shikoku Cancer Center, Matsuyama-shi, Ehime-Ken, 791-0280, Japan|Hokkaido University Hospital, Sapporo-shi, Hokkaido, 060-8648, Japan|Osaka University Hospital, Suita-shi, Osaka-Fu, 565-0871, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo-To, 104-0045, Japan|Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, 13620, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Seoul National University Hospital, Seul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seul, 03722, Korea, Republic of|Samsung Medical Center, Seul, 06351, Korea, Republic of|Antoni van Leeuwenhoek, Amsterdam, 1066 CX, Netherlands|Erasmus Medisch Centrum, Rotterdam, 3015 AA, Netherlands|Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos, Lisboa, 1169-050, Portugal|Funda??o Champalimaud, Lisboa, 4099-001, Portugal|Centro Hospitalar do Porto, E.P.E - Hospital de Santo Antonio, Porto, 4099-001, Portugal|National University Cancer Institute, Singapore, 119074, Singapore|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, 28050, Spain|Clinica Universidad de Navarra, Pamplona, 31008, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Instituto Valenciano de Oncologia IVO, Valencia, 46009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46026, Spain|Karolinska universitetssjukhuset - Solna, Solna, 171 64, Sweden|Akademiska Sjukhuset, Uppsala, 75185, Sweden|Acibadem Adana Hospital, Adana, 01130, Turkey|Acibadem Maslak Hospital, Istanbul, 34457, Turkey|Namik Kemal University, Tekirda?, 59100, Turkey|Sarah Cannon Research Institute UK, London, Greater London, W1G 6AD, United Kingdom Less << |
Tags: Futibatinib | TAS-120 | TAS120 | TAS 120 | FGFR Inhibitor | Fibroblast growth factor receptor | FGFR1 Inhibitor | FGFR2 Inhibitor | FGFR3 Inhibitor | FGFR4 Inhibitor | 1448169-71-8
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL